DUBLIN – (COMMERCIAL THREAD) – The report “Global Gene Expression Markets, 2021-2028” has been added to ResearchAndMarkets.com offer.

The global gene expression market size is expected to reach $ 19.4 billion by 2028, registering a CAGR of 9.96% from 2021 to 2028.

The increase in investments for the development of alternative drug discovery approaches coupled with an increase in research activities for genetic studies is expected to drive the global market.

Awareness of the potential application of genetic studies has led to increased investment for the development and launch of new products. For example, in August 2020, Lexogen GmbH launched the QuantSeq-Pool Sample-Barcoded 3 ‘mRNA-Seq Library Prep Kit to accelerate multiplexing capabilities during gene expression profiling. The company’s new QuantSeq-Pool kit also makes it easy to sequencing up to 36,864 RNA samples in parallel, reducing costs and time.

In addition, the drop in costs associated with sequencing has emerged as a major driver in recent years. According to the National Human Genome Research Institute (NHGRI), the cost of genome sequencing has fallen from $ 46.77,000 in 2010 to $ 0.689,000 in 2020. This dramatic 98.5% drop in sequencing costs over a decade has increased research involving the profiling of genomic expression. studies.

Highlights of the Gene Expression Market Report

• CDNA synthesis and conversion dominated the process segment in 2020. Strong demand for personalized medicine coupled with technological advances in sequencing techniques has enhanced the application of cDNA synthesis to produce genomic libraries

• In addition, the introduction of systems providing direct synthesis of libraries has eliminated the need for prior steps, increasing the revenue share.

• Kits and reagents generated the highest revenue in 2020 due to their high usage during the process

• In addition, continuous innovation in kits and reagents dedicated to specific applications contributes to the highest share of the segment.

• High-Plex capacity is expected to register the fastest CAGR during the forecast period due to higher precision and increased application in cancer research

• RNA exp. was the most revenue-generating technique in 2020 due to greater adoption of exp RNA. analysis

• Additionally, the introduction of high throughput validation methods, such as targeted RNA sequencing, which are useful in broader screening technologies, has increased revenue generation in the segment.

• The drug discovery and development segment accounted for the largest share of revenue in 2020 as Gene Exp. Signature (GES) is commonly used for the development of new molecules for multifactorial cellular diseases such as cancer, diabetes, tuberculosis, malaria, AIDS and other infectious diseases

• North America was the dominant regional market in 2020. This can be attributed to the high adoption of advanced genetic experimentation. technology in the region

• Major market players, such as Thermo Fisher Scientific, Inc. and Agilent Technologies, have taken strategic initiatives to strengthen their market position

• In March 2020, Thermo Fisher Scientific, Inc. released the PowerTrack SYBR Green PCR Master Mix for the real-time PCR workflow. The product is intended to amplify targets for precise analysis

Company Profiles

• QIAGEN

• Quest Diagnostics Incorporated

• F. Hoffmann-La Roche Ltée

• Illumina, Inc.

• Novogene Company

• PerkinElmer, Inc.

• Bio-Rad Laboratories, Inc.

• Thermo Fisher Scientific, Inc.

• Agilent Technologies

• GE Health Dharmacon, Inc.

• Promega Company

• Luminex Company

• Oxford Genetic Technology

• TAKARA BIO, INC.

• Danaher

• ELITech Group

• A myriad of genetics

• AutoGenomics

• Biocartis

• IntegraGen.

• Interpace Diagnostics, LLC.

• Fluidigm Corporation

For more information on this report, visit https://www.researchandmarkets.com/r/bcokue